Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease: Survival Estimates From the EMPA-REG OUTCOME Trial

被引：31
|
作者：
Claggett, Brian [1 ]
Lachin, John M. [2 ]
Hantel, Stefan [3 ]
Fitchett, David [4 ,5 ]
Inzucchi, Silvio E. [6 ]
Woerle, Hans J. [7 ]
George, Jyothis T. [7 ]
Zinman, Bernard [5 ,8 ]
机构：
[1] Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA
[2] George Washington Univ, Biostat Ctr, Rockville, MD USA
[3] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[4] St Michaels Hosp, Div Cardiol, Toronto, ON, Canada
[5] Univ Toronto, Toronto, ON, Canada
[6] Yale Univ, Endocrinol Sect, Sch Med, New Haven, CT USA
[7] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[8] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
来源：
CIRCULATION | 2018年 / 138卷 / 15期
关键词：
cardiovascular diseases; diabetes mellitus; empagliflozin;
D O I：
10.1161/CIRCULATIONAHA.118.033810
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1599 / 1601
页数：3
相关论文
共 50 条
  • [31] Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease The EMPA-HEART CardioLink-6 Randomized Clinical Trial
    Verma, Subodh
    Mazer, C. David
    Yan, Andrew T.
    Mason, Tamique
    Garg, Vinay
    Teoh, Hwee
    Zuo, Fei
    Quan, Adrian
    Farkouh, Michael E.
    Fitchett, David H.
    Goodman, Shaun G.
    Goldenberg, Ronald M.
    Al-Omran, Mohammed
    Gilbert, Richard E.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    Juni, Peter
    Zinman, Bernard
    Connelly, Kim A.
    CIRCULATION, 2019, 140 (21) : 1693 - 1702
  • [32] Empagliflozin improves left ventricular ejection fraction and end systolic volume in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD trial
    Ghanbari, Samin
    Gohari, Sepehr
    Reshadmanesh, Tara
    Mahjani, Mahsa
    Arsang-Jang, Shahram
    Ismail-Beigi, Faramarz
    Dadashi, Mohsen
    Chiti, Hossein
    Asgari, Atieh
    Taheri, Homa
    Zolfkhani, Ozra
    Ahangar, Hassan
    JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2024, 23 (01) : 1081 - 1091
  • [33] Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus
    Shinozaki, Satoshi
    Tahara, Toshiyuki
    Lefor, Alan Kawarai
    Ogura, Masahito
    JOURNAL OF MEDICAL INVESTIGATION, 2020, 67 (3-4) : 280 - 284
  • [34] Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial
    Archana Rai
    Kim A. Connelly
    Subodh Verma
    C. David Mazer
    Hwee Teoh
    Ming-Yen Ng
    Idan Roifman
    Adrian Quan
    Marina Pourafkari
    Laura Jimenez-Juan
    Venkat Ramanan
    Yin Ge
    Djeven P. Deva
    Andrew T. Yan
    Acta Diabetologica, 2022, 59 : 575 - 578
  • [35] Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial
    Rai, Archana
    Connelly, Kim A.
    Verma, Subodh
    Mazer, C. David
    Teoh, Hwee
    Ng, Ming-Yen
    Roifman, Idan
    Quan, Adrian
    Pourafkari, Marina
    Jimenez-Juan, Laura
    Ramanan, Venkat
    Ge, Yin
    Deva, Djeven P.
    Yan, Andrew T.
    ACTA DIABETOLOGICA, 2022, 59 (04) : 575 - 578
  • [36] Long-term survival analysis of patients with non-small cell lung cancer complicated with type 2 diabetes mellitus
    Wang, Gaoxiang
    Li, Xuejiao
    Xiong, Ran
    Wu, Hanran
    Xu, Meiqing
    Xie, Mingran
    THORACIC CANCER, 2020, 11 (05) : 1309 - 1318
  • [37] Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial
    Katakami, Naoto
    Mita, Tomoya
    Yoshii, Hidenori
    Shiraiwa, Toshihiko
    Yasuda, Tetsuyuki
    Okada, Yosuke
    Kurozumi, Akira
    Hatazaki, Masahiro
    Kaneto, Hideaki
    Osonoi, Takeshi
    Yamamoto, Tsunehiko
    Kuribayashi, Nobuichi
    Maeda, Kazuhisa
    Yokoyama, Hiroki
    Kosugi, Keisuke
    Ohtoshi, Kentaro
    Hayashi, Isao
    Sumitani, Satoru
    Tsugawa, Mamiko
    Ryomoto, Kayoko
    Kato, Ken
    Nakamura, Tadashi
    Kawashima, Satoshi
    Sato, Yasunori
    Watada, Hirotaka
    CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
  • [38] Nationwide comparison of long-term survival and cardiovascular morbidity after acute aortic aneurysm repair in patients with and without type 2 diabetes
    Taimour, Soumia
    Franzen, Stefan
    Zarrouk, Moncef
    Acosta, Stefan
    Nilsson, Peter
    Miftaraj, Mervete
    Eliasson, Bjorn
    Svensson, Ann-Marie
    Gottsater, Anders
    JOURNAL OF VASCULAR SURGERY, 2020, 71 (01) : 30 - +
  • [39] Long-term renoprotective effect of luseogliflozin in type 2 diabetes patients: CHikushi Anti-diabetes mellitus Trial-Lusefi (CHAT-Lu)
    Takamiya, Yosuke
    Imanaga, Chiyori
    Abe, Ichiro
    Kobayashi, Kunihisa
    Ike, Amane
    Kawamura, Akira
    Urata, Hidenori
    DRUG DISCOVERIES AND THERAPEUTICS, 2024, 18 (06) : 336 - 342
  • [40] Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Results From the LEADER Trial
    Mann, Johannes F. E.
    Fonseca, Vivian
    Mosenzon, Ofri
    Raz, Itamar
    Goldman, Bryan
    Idorn, Thomas
    von Scholten, Bernt Johan
    Poulter, Neil R.
    CIRCULATION, 2018, 138 (25) : 2908 - 2918
12345